COX19: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: COX19

NCBI ID: G90639

COX19

COX19: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The pain can be caused by various conditions, such as fibromyalgia, rheumatoid arthritis, cancer, and neurorological disorders. In addition, chronic pain can lead to significant functional limitations, decreased quality of life, and increased disability. Therefore, the development of new treatments for chronic pain is of great interest.

COX19, a protein known as cytochrome c oxidase assembly factor (COX19), has been identified as a potential drug target and biomarker for chronic pain. COX19 is a key enzyme in the cytochrome c oxidase (CYTOCOMPOSITOR) family, which is involved in various cellular processes, including inflammation, DNA damage repair, and cell signaling. In the context of chronic pain, COX19 has been shown to play a crucial role in modulating pain perception and persistence.

During the pain signaling process, COX19 is involved in the production of pro-inflammatory cytokines, such as prostaglandins E2 (PGE2) and prostaglandin F2 (PGF2), which contribute to pain perception and persistence. COX19 has been shown to regulate the activity of various transcription factors, including nuclear factor kappa B (NFKB), transcription factor yahoo (NFY), and regulatory genes (RG), thereby affecting pain expression.

In addition, COX19 has been shown to modulate the activity of pain modulators, such as GPR95 and GPR117, which are involved in the modulation of pain perception. GPR95 is a G protein-coupled receptor that is known to play a role in the modulation of pain perception, while GPR117 is a G protein-coupled receptor that is involved in pain modulation. COX19 has been shown to regulate the activity of GPR95 and GPR117, thereby modulating pain perception.

Furthermore, COX19 has been shown to play a role in the modulation of pain-related neurotransmitters, such as dopamine (DA) and opioids (OPs), which are involved in the modulation of pain perception. COX19 has been shown to regulate the activity of the neurotransmitter tyrosine hydroxylase (NTH), which is involved in the modulation of DA neurotransmission. Additionally, COX19 has been shown to regulate the activity of the opioid receptor (OR), which is involved in the modulation of Ops neurotransmission.

In conclusion, the identification of COX19 as a potential drug target and biomarker for chronic pain is of great interest. The modulation of pain perception by COX19 makes it a promising target for the development of new treatments for chronic pain. Future research will be focused on the development of small molecules and other therapeutic compounds that can inhibit the activity of COX19 and modulate pain perception.

Protein Name: Cytochrome C Oxidase Assembly Factor COX19

Functions: Required for the transduction of an SCO1-dependent redox signal from the mitochondrion to ATP7A to regulate cellular copper homeostasis (PubMed:23345593). May be required for the assembly of mitochondrial cytochrome c oxidase (By similarity)

The "COX19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COX19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets